8-K

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934

Date of report (Date of earliest event reported): January 20, 2011

NxSTAGE MEDICAL, INC.

(Exact name of registrant as specified in its charter)

Delaware	000-51567	04-3454702
(State or other jurisdiction of	(Commission File Number)	(I.R.S. Employer Identification No.)
incorporation or organization)

439 S. Union St, 5th Floor, Lawrence, MA	01843
(Address of principal executive offices)	(Zip Code)

(978) 687-4700
(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

(b) On January 20, 2011, Jonathan Silverstein, a director of NxStage Medical, Inc. (“NxStage” or the “Company”) resigned from the Board of Directors of NxStage, and all committees thereof, due to other business and personal commitments, effective immediately. At the time of his resignation, Mr. Silverstein was a member of the Nominating and Corporate Governance Committee.

(d) On January 20, 2011 the Board of Directors appointed Nancy J. Ham to its Board of Directors. The appointment of Ms. Ham to the Board fills the vacancy created by the resignation of Mr. Silverstein, and maintains the total number of directors on the Board at eight. Ms. Ham was not appointed to any committees of NxStage’s Board of Directors.

Ms. Ham will be entitled to receive compensation for her service on the Board of Directors consistent with NxStage’s director compensation program for non-employee directors, as described under the heading Director Compensation in NxStage’s proxy statement for its 2010 Annual Meeting of Stockholders as filed with the Securities and Exchange Commission on April 29, 2010, which description is incorporated in this Form 8-K by reference.

In connection with Ms. Ham’s appointment to the Board of Directors, she and the Company will enter into the Company’s standard form of indemnification agreement for directors, the form of which was previously filed as Exhibit 10.21 to the Company’s registration statement on Form S-1 (File No. 333-126711).

Item 7.01 Regulation FD Disclosure.

A copy of the Company’s press release announcing his appointment dated December 20, 2010 is attached hereto as Exhibit 99.1 and is incorporated in this report by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit
Number	Description
99.1	Press Release dated January 24, 2011

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed by the undersigned hereunto duly authorized.

	NxStage Medical, Inc.
Date: January 24, 2011	By:	/s/ Robert S. Brown
		Robert S. Brown
		Chief Financial Officer

3

EXHIBIT INDEX

Exhibit Number	Description
99.1	Press Release dated January 24, 2011.

4

EX-99.1

Exhibit 99.1

NxStage^® Appoints Nancy J. Ham to Its Board of Directors and
Announces Resignation of Board Member Jonathan T. Silverstein

LAWRENCE, MA, January 24, 2011 — NxStage Medical, Inc. (Nasdaq: NXTM), a leading manufacturer of innovative dialysis products, today announced the addition of Nancy J. Ham to the Company’s Board of Directors and the resignation of Jonathan T. Silverstein.

Mr. Silverstein, General Partner of OrbiMed, joined NxStage’s Board in connection with the Company’s 2008 financing, in which OrbiMed was the lead investor. “Jonathan has been a tremendous asset to NxStage helping set the future strategic direction for the Company,” said Jeff Burbank, Chief Executive Officer of NxStage Medical. “As we work to further strengthen our market leadership in renal care, we are excited to add someone of Nancy’s caliber and industry background to our Board. Nancy is a strong executive and we look forward to benefiting from her insights and experience.”

Ms. Ham is currently President, CEO and director of MedVentive, Inc., a leading provider of physician performance management solutions for healthcare delivery networks and payers. Previously, she served as President of Sentillion, Inc. Before joining Sentillion, Ms. Ham served in various executive capacities at ProxyMed, Inc., including President and COO, and Healtheon/WebMD Corporation.

“I’m very excited about contributing to the growth that I believe NxStage has ahead of them, and to improving patient access around the world to the many reported benefits of daily home therapy with the NxStage System One™,” said Ms. Ham.

About NxStage Medical, Inc.

NxStage Medical, Inc. (Nasdaq: NXTM) is a medical device company, headquartered in Lawrence, Massachusetts, USA, that develops, manufactures and markets innovative products for the treatment of End Stage Renal Disease (ESRD) and acute kidney failure. For more information on NxStage and its products, please visit NxStage’s website at www.nxstage.com.

Forward-Looking Statements

This release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this release that are not clearly historical in nature are forward-looking, and the words “anticipate,” “believe,” “expect,” “estimate,” “plan,” and similar expressions are generally intended to identify forward-looking statements. Examples of these forward-looking statements include statements as to the contributions Ms. Ham will make to NxStage’s performance and

operating results. All forward-looking statements involve risks, uncertainties and contingencies, many of which are beyond NxStage’s control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance or achievements. Certain factors which may affect future operating results are detailed in NxStage’s filings with the Securities and Exchange Commission, including the Quarterly Report on Form 10-Q for the period ending September 30, 2010. In addition, the statements in this press release represent NxStage’s expectations and beliefs as of the date of this press release. NxStage anticipates that subsequent events and developments may cause these expectations and beliefs to change. However, while NxStage may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so, whether as a result of new information, future events, or otherwise. These forward-looking statements should not be relied upon as representing NxStage’s expectations or beliefs as of any date subsequent to the date of this press release.

# # #

Contact:

Kristen K. Sheppard, Esq.
VP, Investor Relations
ksheppard@nxstage.com